Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Company Overview

Iterum Therapeutics PLC is a clinical-stage biopharmaceutical company dedicated to addressing the global threat of antibiotic resistance. Headquartered in Dublin, Ireland, with an operational presence in New Jersey, Iterum focuses on the development and commercialization of novel anti-infective agents designed to combat serious bacterial infections. The company’s research emphasizes oral and intravenous therapies that can be deployed in both hospital and outpatient settings.

The centerpiece of Iterum’s pipeline is sulopenem, a broad-spectrum penem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and other serious infections caused by multidrug-resistant Gram-negative pathogens. Sulopenem’s oral formulation is intended to offer an alternative to existing intravenous therapies, potentially reducing hospitalization time and improving patient compliance. Iterum has completed multiple Phase III clinical trials evaluating the safety and efficacy of sulopenem and is preparing for regulatory submissions in key markets.

In addition to its lead program, Iterum is exploring other potential indications and collaborating with academic institutions and contract research organizations to expand its anti-infective portfolio. The company’s development strategy encompasses the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with plans to extend its reach to regions where antibiotic resistance presents a growing healthcare challenge. Iterum’s manufacturing partnerships aim to ensure scalable production and timely supply of its investigational therapies.

Formed as a spin-out in 2018, Iterum has assembled a leadership team with deep expertise in antimicrobial drug development. Under the guidance of Co-Founder and Chief Executive Officer Mary Claire Haver, supported by a board of directors and senior executives with backgrounds in biotechnology, pharmaceuticals and clinical research, the company remains committed to delivering innovative solutions that address unmet medical needs in infectious disease.

Key Stats

• Today's Range: $1.05 to $1.13
• 50-Day Range: $0.92 to $1.13
• 52-Week Range: $0.81 to $3.02
• Volume: 286,027 shs
• Average Volume: 1.08 million shs
• Market Capitalization: $42.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Iterum Therapeutics Stock Analysis - MarketRank™

Iterum Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 728th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Iterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Iterum Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Iterum Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iterum Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.04% of the float of Iterum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iterum Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iterum Therapeutics has recently increased by 1.71%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iterum Therapeutics does not currently pay a dividend.

Dividend Growth

Iterum Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.04% of the float of Iterum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iterum Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Iterum Therapeutics has recently increased by 1.71%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Iterum Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Iterum Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for ITRM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of Iterum Therapeutics is held by insiders.

Percentage Held by Institutions

Only 9.21% of the stock of Iterum Therapeutics is held by institutions.

ITRM Stock Analysis - Frequently Asked Questions

How have ITRM shares performed this year?

Iterum Therapeutics' stock was trading at $1.77 at the start of the year. Since then, ITRM shares have decreased by 40.4% and is now trading at $1.0550.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) announced its earnings results on Tuesday, May, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.14).
Read the conference call transcript.

When did Iterum Therapeutics' stock split?

Iterum Therapeutics's stock reverse split on Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Iterum Therapeutics IPO?

Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Genetics (ATOS).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ITRM
• CIK: 1659323
• Web: www.iterumtx.com
• Phone: (531) 669-4820
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Iterum Therapeutics: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +696.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -71.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.72
• Quick Ratio: 3.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.15) per share
• Price / Book: -7.53

Miscellaneous

• Outstanding Shares: 40,000,000
• Free Float: 36,320,000
• Market Cap: $45.20 million
• Optionable: Not Optionable
• Beta: 2.79